viewMotif Bio PLC

Motif Bio seeks talks with FDA after iclaprim setback

The Food & Drug Administration has requested more data on the company's antibiotic

It could take up to six weeks before the Motif team can address the issues raised by the regulator

Motif Bio Plc (LON:MTFB, NASDAQ:MFTB) said it has requested a meeting with the Food & Drug Administration after the US watchdog said it wouldn’t be giving the regulatory green light to the company’s antibiotic, iclaprim.

In what’s called a complete response letter, the FDA indicated additional data would be required “to further evaluate the risk for liver toxicity” before granting approval.

READ: Motif Bio to present positive iclaprim drug data in the US this week

Motif, which developed the treatment for acute bacterial skin and skin structure infections, said it is keen to “to discuss potential options to address the deficiencies”. According to chief executive Graham Lumsden, his team may have to wait between 30-45 days before having the opportunity to do so.

"We look forward to working with the agency to discuss options to advance iclaprim towards approval," he said.

Quick facts: Motif Bio PLC

Price: 0.795 GBX

Market: AIM
Market Cap: £5.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Bango helps to grow paying user base of UAE mobile operator by 20% thanks to...

Bango PLC's (LON:BGO) Anil Malhotra reports back on the results of some work they did earlier this year with du, a mobile operator in the United Arab Emirates (UAE), which was based around the Bango Boost programme. The programme's designed to help partners to grow the business they do...

8 hours, 54 minutes ago

2 min read